Clinical trial
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
NCT00108069 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00108069 |
|---|---|
| Title | Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors |
| Official title | A Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma |
| Intervention type | Drug |
| Interventions | Tamoxifen citrate, Bortezomib |
| Enrollment | 43 |
| Start date | Apr 1, 2005 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Apr 13, 2005 |
| Last update posted | Nov 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: